Cannabidiol for moderate-severe insomnia: a randomized controlled pilot trial of 150 mg of nightly dosing
Narayan AJ, Downey LA, Rose S, Di Natale L, Hayley AC
Published in Journal of Clinical Sleep Medicine
Methodology
Randomised, placebo-controlled, parallel-group pilot with single-blind placebo run-in and 2-week double-blind sublingual dosing of 150 mg cannabidiol nightly, measured by wrist actigraphy, sleep diaries and validated questionnaires
Key Findings
Insomnia severity, self-reported sleep onset latency, sleep efficiency and wake after sleep onset did not differ between cannabidiol and placebo; the cannabidiol group reported greater well-being and had better objective sleep efficiency after 2 weeks.
Conclusions
Nightly 150 mg cannabidiol did not improve insomnia symptoms relative to placebo in this pilot trial.
Limitations
Small pilot sample, short duration, single dose level, and mixed objective versus subjective findings.
Related Health Concerns
Study Details
Access Study
Disclosures
Funding
Not reported
This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.